VIDEO: Apellis plans to submit NDA for pegcetacoplan in first half of 2022

NEW ORLEANS — In this Healio Video Perspective from the Eyecelerator meeting, Cedric Francois, MD, PhD, Apellis co-founder and CEO, discusses study results and FDA communication regarding intravitreal pegcetacoplan for geographic atrophy.